TRPC5 and focal segmental glomerulosclerosis: The pyridazinone compound GFB-8438 (Figure 2) was a highly selective, potent TRPC5 antagonist, which specifically interacted with the TRPC5-Rac1 pathway in podocytes to attenuate FSGS and diabetic nephropathy [20].